Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.71 - $17.11 $447,678 - $715,198
-41,800 Reduced 89.51%
4,900 $61,000
Q2 2024

Jul 31, 2024

SELL
$3.89 - $20.97 $544,989 - $2.94 Million
-140,100 Reduced 75.0%
46,700 $591,000
Q1 2024

May 14, 2024

BUY
$3.76 - $6.02 $122,200 - $195,650
32,500 Added 21.06%
186,800 $892,000
Q4 2023

Feb 14, 2024

BUY
$4.8 - $7.67 $374,400 - $598,260
78,000 Added 102.23%
154,300 $740,000
Q3 2023

Nov 14, 2023

SELL
$6.81 - $9.74 $14,982 - $21,428
-2,200 Reduced 2.8%
76,300 $552,000
Q2 2023

Aug 14, 2023

SELL
$6.67 - $9.52 $127,397 - $181,832
-19,100 Reduced 19.57%
78,500 $583,000
Q1 2023

May 15, 2023

BUY
$5.76 - $12.48 $562,176 - $1.22 Million
97,600 New
97,600 $676,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $630M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Skaana Management L.P. Portfolio

Follow Skaana Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skaana Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Skaana Management L.P. with notifications on news.